Amgen 2015 Annual Report Download - page 50

Download and view the complete annual report

Please find page 50 of the 2015 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 132

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132

42
Results of Operations
Product sales
Worldwide product sales were as follows (dollar amounts in millions):
Year ended
December 31,
Year ended
December 31,
Year ended
December 31,
2015 Change 2014 Change 2013
ENBREL $ 5,364 14 % $ 4,688 3 % $ 4,551
Neulasta®4,715 3 % 4,596 5 % 4,392
Aranesp®1,951 1 % 1,930 1 % 1,911
EPOGEN®1,856 (9)% 2,031 4 % 1,953
Sensipar®/Mimpara®1,415 22 % 1,158 6 % 1,089
XGEVA®1,405 15 % 1,221 20 % 1,019
Prolia®1,312 27 % 1,030 38 % 744
NEUPOGEN®1,049 (9)% 1,159 (17)% 1,398
Other products 1,877 24 % 1,514 33 % 1,135
Total product sales $ 20,944 8 % $ 19,327 6 % $ 18,192
Total U.S. $ 16,523 12 % $ 14,732 5 % $ 14,045
Total ROW 4,421 (4)% 4,595 11 % 4,147
Total product sales $ 20,944 8 % $ 19,327 6 % $ 18,192
Future sales of our products will depend, in part, on the factors discussed in the Overview, Part 1—Item 1. Business—
Marketing, Distribution and Selected Marketed Products—Competition, Part 1—Item 1A. Risk Factors and any additional factors
discussed in the individual product sections below. In addition, for a list of our products’ significant competitors, see Part 1—Item
1. Business—Marketing, Distribution and Selected Marketed Products—Competition.
ENBREL
Total ENBREL sales by geographic region were as follows (dollar amounts in millions):
Year ended
December 31,
Year ended
December 31,
Year ended
December 31,
2015 Change 2014 Change 2013
ENBREL — U.S. $ 5,099 16 % $ 4,404 3 % $ 4,256
ENBREL — Canada 265 (7)% 284 (4)% 295
Total ENBREL $ 5,364 14 % $ 4,688 3 % $ 4,551
The increase in ENBREL sales for 2015 was driven primarily by an increase in net selling price offset partially by the impact
of competition.
The increase in ENBREL sales for 2014 was driven primarily by an increase in net selling price offset partially by unfavorable
changes in wholesaler and, based on prescription data, end-user inventories.
Neulasta®
Total Neulasta® sales by geographic region were as follows (dollar amounts in millions):
Year ended
December 31,
Year ended
December 31,
Year ended
December 31,
2015 Change 2014 Change 2013
Neulasta® — U.S. $ 3,891 7 % $ 3,649 4% $ 3,499
Neulasta® — ROW 824 (13)% 947 6% 893
Total Neulasta®$ 4,715 3 % $ 4,596 5% $ 4,392